News
CANF
2.100
-1.87%
-0.040
Weekly Report: what happened at CANF last week (0928-1002)?
Weekly Report · 2d ago
Can-Fite Buy Rating Reaffirmed as Clinical Momentum Builds and $8 Price Target Remains Unchanged
TipRanks · 09/29 10:35
Can-Fite BioPharma Files Prospectus For Offering ~6.599M Ordinary Shares On Behalf Of Selling Shareholders
Benzinga · 09/28 18:00
Weekly Report: what happened at CANF last week (0921-0925)?
Weekly Report · 09/28 09:35
Weekly Report: what happened at CANF last week (0914-0918)?
Weekly Report · 09/21 09:35
Weekly Report: what happened at CANF last week (0907-0911)?
Weekly Report · 09/14 09:37
Can-Fite Case Report Shows Namodenoson Bridged Decompensated Cirrhosis Patient to Liver Transplant
TipRanks · 09/09 11:27
Can-Fite Biopharma GAAP EPS of -$1.24, revenue of $0.2M
Seeking Alpha · 09/09 05:07
Can-Fite Reports Q2 2026 Results As Liver Cancer Survival Exceeds Expectations
NASDAQ · 09/08 15:06
Can-Fite BioPharma Reports Mid-2026 Results and Updates Drug Development Programs
TipRanks · 09/08 12:46
Can Fite Biofarma H1 EPS $(1.24) Beats $(1.43) Estimate, Sales $202.000K, Same YoY
Benzinga · 09/08 12:30
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Barchart · 09/08 07:20
Weekly Report: what happened at CANF last week (0831-0904)?
Weekly Report · 09/07 09:35
Can-Fite BioPharma Cuts Warrant Exercise Price to Secure $4 Million Inducement Financing
TipRanks · 09/03 16:01
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga · 09/02 17:06
Can-Fite BioPharma Evaluates Earlier Interim Analysis for Key Liver Cancer Study
Benzinga · 09/02 15:48
Can-Fite Enters Warrant Exercise Deal For $4 Mln, Shares To Be Issued At Discount; Stock Plunges
NASDAQ · 09/02 14:28
Can-Fite BioPharma Raises $4 Million Through Warrant Exercise to Fund Late-Stage Drug Pipeline
TipRanks · 09/02 14:17
Can-Fite BioPharma To Receive ~$4M From Exercise Of 1,591,738 Warrants At Reduced $2.50/ADS Price
Benzinga · 09/02 13:05
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga · 09/02 12:07
More
Webull provides a variety of real-time CANF stock news. You can receive the latest news about Can-Fite BioPharma Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About CANF
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.